Market Place
Sourcing Support
FDA Restricts Bluebird Bio Therapy Skysona After Cancer Reports
12 Aug 2025 //
FIERCE PHARMA
bluebird bio Bolsters Management Team with Appointments
01 Jul 2025 //
CONTRACTPHARMA
Carlyle, SK Capital End bluebird bio Tender Offer
30 May 2025 //
BUSINESSWIRE
bluebird Urges Shareholders to Tender Shares Pre-Deal
27 May 2025 //
BUSINESSWIRE
Carlyle, SK Capital, bluebird bio Update Tender Instructions
16 May 2025 //
BUSINESSWIRE
Carlyle, SK Capital, bluebird bio Amend Merger Agreement
14 May 2025 //
BUSINESSWIRE
Bluebird bio warns of bankruptcy as buyout faces another delay
14 May 2025 //
FIERCE PHARMA
bluebird Stockholders to Tender Shares for Carlyle Acquisition
09 May 2025 //
BUSINESSWIRE
Ayrmid misses deadline for offer to Private Equity bid for Bluebird
17 Apr 2025 //
ENDPTS
bluebird Says Ayrmid Lacks Offer and Funding Commitment
16 Apr 2025 //
BUSINESSWIRE
Bluebird bio receives non-binding bid for up to $110.5 M
29 Mar 2025 //
REUTERS
Once valued at $10B, struggling bluebird bio sold for $29M
22 Feb 2025 //
FIERCE PHARMA
CDMO Resilience plots job cuts at former bluebird bio facility
08 Jan 2025 //
FIERCE PHARMA
bluebird bio Announces 1-for-20 Reverse Stock Split
04 Dec 2024 //
BUSINESSWIRE
bluebird bio Reports Q3 2024 Results & 2024 Guidance
14 Nov 2024 //
BUSINESSWIRE
bluebird bio Adjourns Stockholder Meeting, Announces Q3 Results
06 Nov 2024 //
BUSINESSWIRE
bluebird bio to Present Gene Therapy Data at ASH 2024
05 Nov 2024 //
BUSINESSWIRE
bluebird bio Announces Receipt of Expected Notices from Nasdaq
23 Aug 2024 //
BUSINESSWIRE
Bluebird Stock Falls 18% On Slow Lyfgenia Gene Therapy Uptake
14 Aug 2024 //
FIERCE PHARMA
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2024 //
BUSINESSWIRE
Bluebird bio`s gene therapy fertility support program gets thumbs down from HHS
22 Jul 2024 //
FIERCE PHARMA
bluebird Reports Inducement Grant to CFO Sterling Under Nasdaq Listing Rule
03 Jul 2024 //
BUSINESSWIRE
Neurocrine CEO Retires, Bluebird Appoints 5th CFO In 3 Years
31 May 2024 //
ENDPTS
bluebird bio Appoints O. James Sterling as Chief Financial Officer
29 May 2024 //
BUSINESSWIRE
BLUE Investor Alert: Kirby McInerney Notes Lead Plaintiff Deadline
17 May 2024 //
BUSINESSWIRE
bluebird bio schedules first quarter 2024 results call.
06 May 2024 //
BUSINESSWIRE
bluebird bio Announces Receipt of Expected Notice from Nasdaq
26 Apr 2024 //
BUSINESSWIRE
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Apr 2024 //
BUSINESSWIRE
bluebird bio Reports Fourth Quarter and 2023 Annual Results
26 Mar 2024 //
BUSINESSWIRE
Bluebird discusses Lyfgenia launch details and accounting errors
26 Mar 2024 //
FIERCE PHARMA
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
18 Mar 2024 //
BUSINESSWIRE
Bluebird secures $175M loan from Hercules Capital
18 Mar 2024 //
FIERCE PHARMA
bluebird bio Announces First Outcomes-Based Agreement with Medicaid
11 Mar 2024 //
BUSINESSWIRE
JPM24: Bluebird CEO defends Lyfgenia pricing premium, EU retreat
10 Jan 2024 //
FIERCE PHARMA
Blueprint to pull Gavreto in certain markets
09 Jan 2024 //
ENDPTS
bluebird bio Provides Update on Commercial Launch Progress
08 Jan 2024 //
BUSINESSWIRE
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
18 Dec 2023 //
BUSINESSWIRE
Data From bluebird’s Program in Sickle Cell Disease Support Durable Benefits
09 Dec 2023 //
BUSINESSWIRE
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher
30 Oct 2023 //
BUSINESSWIRE
Bluebird Bio to Host Third Quarter 2023 Financial Results Conference Call
24 Oct 2023 //
BUSINESSWIRE
Bluebird tweaks partnership with Lonza to boost Zynteglo
27 Sep 2023 //
ENDPTS
bluebird bio Announces September Investor Events
05 Sep 2023 //
BUSINESSWIRE
Bluebird bio to Host Second Quarter 2023 Financial Results Conference
25 Jul 2023 //
BUSINESSWIRE
bluebird bio Reports1Q 2023 FYR and Highlights Operational Progress
09 May 2023 //
BUSINESSWIRE
bluebird bio Announces 1Q 2023 Earnings Date and Upcoming Investor Events
27 Apr 2023 //
BUSINESSWIRE
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 2023 //
BUSINESSWIRE
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
18 Jan 2023 //
BUSINESSWIRE
Bluebird bio Announces Pricing of $120 Million Public Offering of Common Stock
18 Jan 2023 //
BUSINESSWIRE
bluebird bio Provides Update on Launch Progress & 2023 Financial Outlook
09 Jan 2023 //
BUSINESSWIRE
bluebird bio Sells Second Priority Review Voucher for $95 Million
06 Jan 2023 //
BUSINESSWIRE
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023 //
BUSINESSWIRE
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
03 Jan 2023 //
BUSINESSWIRE
Bluebird sells regulatory fast pass to Argenx for $102M
30 Dec 2022 //
BIOPHARMADIVE
FDA lifts hold on Bluebird’s sickle cell gene therapy
20 Dec 2022 //
BIOPHARMADIVE
bluebird bio Sells Priority Review Voucher for $102 Million
30 Nov 2022 //
BUSINESSWIRE
Bluebird has sold a priority review voucher to argenx
30 Nov 2022 //
FIERCEPHARMA
bluebird bio Reports Third Quarter 2022 Financial Results
07 Nov 2022 //
BUSINESSWIRE
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
02 Nov 2022 //
BUSINESSWIRE
2 biotechs pen licensing pact for cell therapy cancer platform
27 Oct 2022 //
FIERCEBIOTECH
